Home
ATNM
ATNM News

Latest Actinium Pharmaceuticals Inc. (Delaware) (ATNM) News on November 18, 2024

ATNM

Associated Press Finance

3 days ago

Actinium: Q3 Earnings Snapshot

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

ATNM

PR Newswire

13 days ago

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

ATNM

Zacks

a month ago

All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy

Actinium Pharmaceuticals reports data from Phase III trial of AML treatment

ATNM

Clinical Trials Arena

2 months ago

Actinium Pharmaceuticals reports data from Phase III trial of AML treatment

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology

ATNM

PR Newswire

2 months ago

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology

ATNM

MT Newswires

3 months ago

B. Riley Downgrades Actinium Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $2 From $16

ATNM

Associated Press Finance

3 months ago

Actinium: Q2 Earnings Snapshot

ATNM

MT Newswires

3 months ago

Sector Update: Health Care Stocks Fall in Afternoon Trading

ATNM

MT Newswires

3 months ago

Sector Update: Health Care Stocks Lean Lower Premarket Monday

ATNM

MT Newswires

3 months ago

Actinium Pharmaceuticals Shares Plunge After FDA Says Iomab-B Trial Does Not Support Planned BLA Filing

ATNM

MT Newswires

3 months ago

Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.

Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications

ATNM

PR Newswire

4 months ago

Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications

ATNM

MT Newswires

4 months ago

Actinium Pharmaceuticals Gets FDA Approval for Sickle Cell Disease Treatment Study

Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University

ATNM

PR Newswire

4 months ago

Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University

Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US

ATNM

PR Newswire

4 months ago

Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US

ATNM

Zacks

5 months ago

Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?

Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions

ATNM

Newsfile

5 months ago

Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions

Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)

ATNM

Newsfile

5 months ago

Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)

Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress

ATNM

PR Newswire

5 months ago

Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress

Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial

ATNM

PR Newswire

5 months ago

Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial

Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

ATNM

PR Newswire

5 months ago

Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

ATNM

PR Newswire

5 months ago

Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?

ATNM

Zacks

5 months ago

Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?

Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity

ATNM

PR Newswire

6 months ago

Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial

ATNM

PR Newswire

6 months ago

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial

ATNM

MT Newswires

6 months ago

Stephens Initiates Actinium Pharmaceuticals With Overweight Rating, $25 Price Target

Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

ATNM

PR Newswire

6 months ago

Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern

ATNM

PR Newswire

6 months ago

Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern

$Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting$

ATNM

PR Newswire

7 months ago

Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting

$Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting$

ATNM

PR Newswire

8 months ago

Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting

Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy

ATNM

PR Newswire

8 months ago

Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy

Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand

ATNM

PR Newswire

8 months ago

Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand

$Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®$

ATNM

PR Newswire

9 months ago

Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

ATNM

InvestorPlace

9 months ago

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

$Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®$

ATNM

PR Newswire

9 months ago

Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

NEUBERGER BERMAN HIGH YIELD STRATEGIES FUND ANNOUNCES MONTHLY DISTRIBUTION

ATNM

PR Newswire

10 months ago

NEUBERGER BERMAN HIGH YIELD STRATEGIES FUND ANNOUNCES MONTHLY DISTRIBUTION

ATNM

Business Wire

10 months ago

Templeton Emerging Markets Income Fund ("TEI" or the "Fund") Announces Notification of Sources of Distributions

ATNM

GlobeNewswire

10 months ago

Southern California Bancorp and California BanCorp Announce a Merger of Equals to Create a Premier California Business Bank

ATNM

Thomson Reuters StreetEvents

10 months ago

Q4 2023 First Internet Bancorp Earnings Call

SOPHiA GENETICS Supports Genetic Testing in Brazil

ATNM

PR Newswire

10 months ago

SOPHiA GENETICS Supports Genetic Testing in Brazil

Lantronix Appoints Christa Steele to Its Board of Directors

ATNM

GlobeNewswire

10 months ago

Lantronix Appoints Christa Steele to Its Board of Directors

First Internet (INBK) Reports Q4 Earnings: What Key Metrics Have to Say

ATNM

Zacks

10 months ago

First Internet (INBK) Reports Q4 Earnings: What Key Metrics Have to Say

First Internet Bancorp (INBK) Q4 Earnings and Revenues Surpass Estimates

ATNM

Zacks

10 months ago

First Internet Bancorp (INBK) Q4 Earnings and Revenues Surpass Estimates

First Internet Bancorp (INBK) Reports Solid Q4 and Full Year 2023 Earnings Growth

ATNM

GuruFocus.com

10 months ago

First Internet Bancorp (INBK) Reports Solid Q4 and Full Year 2023 Earnings Growth

CONSOL Energy (CEIX) Returned 61% Despite 25% Fall in Estimates

ATNM

Insider Monkey

10 months ago

CONSOL Energy (CEIX) Returned 61% Despite 25% Fall in Estimates

Here’s Why Saga Communications (SGA) Increased in Q4

ATNM

Insider Monkey

10 months ago

Here’s Why Saga Communications (SGA) Increased in Q4

DLH to Announce Fiscal 2024 First Quarter Financial Results

ATNM

GlobeNewswire

10 months ago

DLH to Announce Fiscal 2024 First Quarter Financial Results

At US$16.29, Is DLH Holdings Corp. (NASDAQ:DLHC) Worth Looking At Closely?

ATNM

Simply Wall St.

10 months ago

At US$16.29, Is DLH Holdings Corp. (NASDAQ:DLHC) Worth Looking At Closely?

SOUTHERN CALIFORNIA BANCORP ANNOUNCES THE RETIREMENT OF CHAIRMAN EMERITUS AND DIRECTOR JOHN FARKASH

ATNM

GlobeNewswire

10 months ago

SOUTHERN CALIFORNIA BANCORP ANNOUNCES THE RETIREMENT OF CHAIRMAN EMERITUS AND DIRECTOR JOHN FARKASH

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

ATNM

GlobeNewswire

10 months ago

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

Office Properties Income Trust Fourth Quarter 2023 Conference Call Scheduled for Friday, February 16th

ATNM

Business Wire

10 months ago

Office Properties Income Trust Fourth Quarter 2023 Conference Call Scheduled for Friday, February 16th

MiX Telematics Sets Third Quarter Fiscal Year 2024 Conference Call for February 1, 2024, at 8:00 a.m. ET and 3:00 p.m. SAST

ATNM

Business Wire

10 months ago

MiX Telematics Sets Third Quarter Fiscal Year 2024 Conference Call for February 1, 2024, at 8:00 a.m. ET and 3:00 p.m. SAST

Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How

ATNM

Zacks

10 months ago

Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How

ATNM

Business Wire

10 months ago

Franklin Templeton Closed-End Funds Announce Share Repurchases for the Fourth Quarter of 2023

Office Properties Income Trust Announces 2023 Dividend Allocations

ATNM

Business Wire

10 months ago

Office Properties Income Trust Announces 2023 Dividend Allocations

Sidoti Events, LLC's Virtual January Micro-Cap Conference

ATNM

ACCESSWIRE

10 months ago

Sidoti Events, LLC's Virtual January Micro-Cap Conference

Enhabit (NYSE:EHAB) Has Some Difficulty Using Its Capital Effectively

ATNM

Simply Wall St.

10 months ago

Enhabit (NYSE:EHAB) Has Some Difficulty Using Its Capital Effectively

LuxUrban Hotels Announces that The Royalton by LuxUrban, Trademark Collection® by Wyndham Will Begin Welcoming Guests in January

ATNM

Business Wire

10 months ago

LuxUrban Hotels Announces that The Royalton by LuxUrban, Trademark Collection® by Wyndham Will Begin Welcoming Guests in January

FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

ATNM

GlobeNewswire

10 months ago

FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

Mondee to Participate in 26th Annual Needham Growth Conference

ATNM

GlobeNewswire

10 months ago

Mondee to Participate in 26th Annual Needham Growth Conference

ATNM

Zacks

10 months ago

Zacks.com featured highlights include JAKKS Pacific, The Andersons, RCM Technologies and Tactile Systems Technology

Merck-Harpoon deal, Twilio, Crocs: Trending Tickers

ATNM

Yahoo Finance Video

10 months ago

Merck-Harpoon deal, Twilio, Crocs: Trending Tickers

ATNM

Business Wire

10 months ago

Templeton Emerging Markets Income Fund ("TEI" or the "Fund") Announces Distribution

Is DLH Holdings Corp. (DLHC) Stock Priced for the “Worst Case” Scenario?

ATNM

Insider Monkey

10 months ago

Is DLH Holdings Corp. (DLHC) Stock Priced for the “Worst Case” Scenario?

Resources Connection Inc (RGP) Faces Revenue Decline Amid Economic Challenges in Q2 Fiscal 2024

ATNM

GuruFocus.com

10 months ago

Resources Connection Inc (RGP) Faces Revenue Decline Amid Economic Challenges in Q2 Fiscal 2024

Voyager (VYGR) Gains on Gene Therapy Deal With Novartis

ATNM

Zacks

10 months ago

Voyager (VYGR) Gains on Gene Therapy Deal With Novartis

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

ATNM

GlobeNewswire

10 months ago

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

HF Foods To Participate in the 2024 ICR Conference

ATNM

GlobeNewswire

10 months ago

HF Foods To Participate in the 2024 ICR Conference

Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

ATNM

PR Newswire

10 months ago

Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

ATNM

Business Wire

a year ago

FREYR Battery Completes Redomicile from Luxembourg to the U.S.

HF Foods Group (NASDAQ:HFFG) investors are sitting on a loss of 59% if they invested five years ago

ATNM

Simply Wall St.

a year ago

HF Foods Group (NASDAQ:HFFG) investors are sitting on a loss of 59% if they invested five years ago

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

ATNM

GlobeNewswire

a year ago

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

Forge Bolsters Roster with Strategic Hires to Deliver Greater Value to Private Company Partners, Institutional Investors

ATNM

Business Wire

a year ago

Forge Bolsters Roster with Strategic Hires to Deliver Greater Value to Private Company Partners, Institutional Investors

11 Most Promising Psychedelic Stocks According to Hedge Funds

ATNM

Insider Monkey

a year ago

11 Most Promising Psychedelic Stocks According to Hedge Funds

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

ATNM

GlobeNewswire

a year ago

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Heritage Announces Closing of Primary Public Offering of Shares of Common Stock and Concurrent Private Placement

ATNM

PR Newswire

a year ago

Heritage Announces Closing of Primary Public Offering of Shares of Common Stock and Concurrent Private Placement

ATNM

Business Wire

a year ago

Templeton Emerging Markets Income Fund ("TEI") Announces Change to Managed Distribution Plan

Sleep Number Corporation's (NASDAQ:SNBR) 48% Share Price Surge Not Quite Adding Up

ATNM

Simply Wall St.

a year ago

Sleep Number Corporation's (NASDAQ:SNBR) 48% Share Price Surge Not Quite Adding Up

ATNM

Business Wire

a year ago

FREYR Battery Receives Invitation from U.S. Department of Energy to Submit Part II Application for Giga America Title 17 Loan

ATNM

Business Wire

a year ago

FREYR Battery Receives Shareholder Approval for Redomicile from Luxembourg to the U.S.

Fanhua Inc. (NASDAQ:FANH) Might Not Be As Mispriced As It Looks After Plunging 27%

ATNM

Simply Wall St.

a year ago

Fanhua Inc. (NASDAQ:FANH) Might Not Be As Mispriced As It Looks After Plunging 27%

Insider Sell Alert: CFO Anuj Aggarwal Sells 15,000 Shares of Everspin Technologies Inc (MRAM)

ATNM

GuruFocus.com

a year ago

Insider Sell Alert: CFO Anuj Aggarwal Sells 15,000 Shares of Everspin Technologies Inc (MRAM)

Why Fast-paced Mover Ocwen (OCN) Is a Great Choice for Value Investors

ATNM

Zacks

a year ago

Why Fast-paced Mover Ocwen (OCN) Is a Great Choice for Value Investors

Barings Global Short Duration High Yield Fund Announces December 2023 Monthly Distribution of $0.1056 per Share

ATNM

Business Wire

a year ago

Barings Global Short Duration High Yield Fund Announces December 2023 Monthly Distribution of $0.1056 per Share

When To Sell Growth Stocks: Why This Rule Worked Like Magic For This Small-Cap Leader

ATNM

Investor's Business Daily

a year ago

When To Sell Growth Stocks: Why This Rule Worked Like Magic For This Small-Cap Leader

CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

ATNM

PR Newswire

a year ago

CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

$Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation$

ATNM

PR Newswire

a year ago

Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation

$Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia$

ATNM

PR Newswire

a year ago

Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia

ATNM

Business Wire

a year ago

Leading Independent Proxy Advisory Firms Recommend Shareholders Vote "FOR" the Redomicile of FREYR Battery from Luxembourg to the U.S.

11 Best Stocks to Buy for the Next 10 Years

ATNM

Insider Monkey

a year ago

11 Best Stocks to Buy for the Next 10 Years

$Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition$